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A B S T R A C T
Background
Primary periodic paralyses are rare inherited muscle diseases characterised by episodes of flaccid weakness affecting one or more limbs,
lasting several hours to several days, caused by mutations in skeletal muscle channel genes.
Objectives
The objective of this review was to systematically review treatment of periodic paralyses.
Search methods
We searched the Cochrane Neuromuscular Disease Group Trials Register, MEDLINE (from January 1966 to July 2007), and EMBASE
(from January 1980 to July 2007) and any other available international medical library sources from the University of Milan for
randomised trials.
Selection criteria
We included randomised (including cross-over studies) and quasi-randomised trials in participants with primary periodic paralyses, in
which any form of treatment, including physical therapy and alternative therapies, was compared to placebo or another treatment.
Data collection and analysis
Our primary outcome measure was the change in attack severity or frequency by eight weeks from the start of treatment.
Our secondary outcome measures were: change in muscle strength and mass; change in Quality of Life, using Short Form 36 (SF36)
or similar; preference of treatment strategy; adverse effects at eight weeks.
Main results
Three studies met our inclusion criteria. In one study dichlorphenamide (DCP) vs placebo was tested in two groups of participants:
42 with hypokalemic periodic paralysis (HypoPP) and 31 with hyperkalemic periodic paralysis (HyperPP), based on clinical criteria.
Thirty-four of 42 participants with hypokalemic periodic paralysis completed both treatment phases. For the 34 participants having
attack rate data for both treatment phases, the mean improvement in attack rate (P = 0.02) and severity-weighted attack rate (P =
0.01) on DCP relative to placebo were statistically significant. Fifteen preferred DCP, three placebo and six their baseline medication.
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Twenty-four of 31 participants with hyperkalemic periodic paralysis completed both treatment phases: for the 16 participants who had
attack rate data for both treatment phases, the mean improvement in attack rate (P = 0.006) and in severity-weighted attack rate (P =
0.02) on DCP relative to placebo were significant. Fifteen preferred DCP, one placebo and five their baseline medication.
Acetazolamide proved to improve muscle strength in eight participants with HypoPP in one other study and pinacidil, a potassium
channel opener, also improved muscle strength in 2/4 participants with HypoPP in a third study.
Authors’ conclusions
The largest included study that met our inclusion criteria suggested that DCP was effective in the prevention of episodic weakness
in both hypokalemic and hyperkalemic periodic paralyses. The other two studies provide some evidence that either acetazolamide or
pinacidil may improve muscle strength. However we still lack sufficient evidence to provide full guidelines for the treatment of people
with periodic paralysis.
P L A I N L A N G U A G E S U M M A R Y
Treatment for periodic paralysis
Muscle weakness and attacks of paralysis are two important features of periodic paralyses. Paralytic attacks occur in acute episodes and
can be incapacitating. Attacks may last from several hours to several days according to the type of muscle channel involved. In some
cases permanent muscle weakness can also occur. We are unsure whether such permanent muscle weakness is more likely to develop
if the frequency of attacks is high and therefore might be less likely to occur if attacks are fully prevented by treatment. Although the
treatment of choice in periodic paralysis is generally considered to be acetazolamide, there is no standardised treatment regimen and no
consensus as to when to start treatment. We do not know if acetazolamide treatment prevents any permanent weakness that may occur.
We found two small studies demonstrating an improvement ofmuscle strengthwith pinacidil and acetazolamide. Therewas only one trial
considering treatment of paralytic attacks, demonstrating a decrease in the severity and frequency of the attacks using diclorophenamide.
We did not find other randomised or quasi-randomised studies, but only case reports and anecdotal articles using other drugs to reduce
paralyses attacks. Further research is needed to determine the best treatment for reducing the frequency and severity of attacks and to
treat or prevent permanent muscle weakness.
B A C K G R O U N D
The primary periodic paralyses (PP) are rare muscle diseases (esti-
mated population prevalence of one per 100,000) affecting males
and females of all ages, characterised by episodes of flaccid paresis
affecting one or more limbs. They result from genetic disorders of
ion channels called “channelopathies”.
Hypokalemic periodic paralysis (HypoPP) is caused in 80% of
cases by point mutations in the voltage-gated calcium channel
gene on chromosome 1 (Fontaine 1994; Jurkat-Rott 1994; Ptacek
1994b; Rojas 1991). So far, three calcium channel mutations
have been described (Arg528His, Arg1239His, Arg1239Gly). Hy-
poPP gene may also be due to a gain-of function on the voltage-
gated sodium channel on chromosome 17 (Arg 672His/Gly/Ser,
Arg669His) (Jurkat-Rott 2000; Sternberg 2001).
Hyperkalemic periodic paralysis (HyperPP) is caused by pointmu-
tations in the voltage-gated sodium channel on chromosome 17
(Fontaine 1990; Ptacek 1991). Sodium channelopathies include
not just hyperkalemic periodic paralysis but also paramyotonia
congenita, potassium-aggravated myotonia, (McClatchey 1992;
Ptacek 1991; Ptacek 1992; Heine 1993). So far, about 30 point
mutations in the sodium channel gene have been described.
Andersen-Tawil syndrome (ATS) is another primary periodic
paralysis characterised by episodes of flaccid weakness in the con-
text of normal, low or high serum potassium levels, sometimes
with severe cardiac arrhythmias, including longQTsyndrome, and
skeletal and facial dysmorphic features (Andersen 1971; Sansone
1997; Tawil 1994). Mutations in the potassium channel gene
KCNJ2, are the primary cause of ATS. Twenty-one mutations
have been found in 30 families and have been found to cause the
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developmental, cardiac and muscle episodic electrical phenotypes
of the syndrome (Plaster 2001). Functional and clinical charac-
terisation of mutations on chromosome 17 on the KCNJ2 gene
results in a loss or suppression of the function of the channel
Kir2.1, which is an inward rectifier, have been associated with
LQT7 (TristaniFirouzi 2002). These mutations result in a reduc-
tion of the function of the channel (Bendahhou 2003, Donaldson
2004).
Diagnostic criteria for primary periodic paralyses have been pro-
posed by an expert committee at the 87th European Neuromus-
cular Centre (ENMC) International Workshop in 2000 (Table
1; Table 2). These included mainly clinical criteria (evidence of
flaccid paresis affecting one or more limbs with absent deep ten-
don reflexes during an attack with the typical classical profile of
triggers, age at onset, duration of the attack, positive family his-
tory, response to potassium intake) and laboratory confirmation of
potassium fluctuation (decrease or increase) during the attack. Ad-
ditional criteria were exclusion of other secondary causes of hypo-
or hyperkalemia and the decremental response of the compound
muscle potential after repetitive stimulation (McManis 1986).
Serum potassium is normal between attacks.
In addition to the attacks of weakness, periodic paralysis may be
characterised by permanent muscle weakness and a limb-girdle
myopathymay develop over time (Dalakas 1983; Links 1990). It is
unclearwhether this is directly related to the frequency and severity
of the episodes of flaccid weakness which result in cumulative
damage to the muscle fibers (Dalakas 1983; Links 1990).
Evidence that potassium intake reduces the severity and frequency
of the attacks of weakness in the hypokalemic periodic paralysis,
has longbeenknown.However, even regular potassium intakemay
fail to prevent attacks and escalating use of potassium may cause
gastrointestinal problems. Nonetheless, the serum potassium ab-
normalities in the PP and the response to potassium administra-
tion, provided a rationale for the utilisation of drugs capable of
affecting serum potassium levels, such as the carbonic anhydrase
inhibitors (Griggs 1970; Links 1988).
Acetazolamide is the most commonly used of the carbonic anhy-
drase inhibitors, based on the results of non-randomised, single-
blind trials in hypokalemic periodic paralysis (Griggs 1970; Ptacek
1994a; Resnick 1968). Dichlorphenamide (DCP) is an alterna-
tive carbonic anhydrase inhibitor (Dalakas 1983) with similar but
milder side effects compared with acetazolamide. In general, stud-
ies have aimed to show a reduction in the frequency and severity
of the attacks using these drugs (Bendahhou 2001; Griggs 1970;
Links 1988; Links 1994). Gastrointestinal disturbances (anorexia,
nausea and vomiting), drowsiness, paraesthesias, and electrolyte
imbalance are the most common long term side effects of carbonic
anhydrase inhibitors. Use of steroids and furosemide, during treat-
ment with carbonic anhydrase inhibitors, may precipitate side ef-
fects.
Alternative treatments in hyperkalemic periodic paralysis have in-
cluded reduction of potassium levels either by reducing intake
(Dalakas 1983; Links 1988) or the use of diuretics such as hy-
drochlorothiazide (Links 1994; Ricker 1983).
Themolecular genetic and cellular electrophysiological progress in
the skeletal muscle channelopathies has been significant. Despite
this biomolecular progress, effective treatment options are limited.
The evidence for current treatments for the periodic paralyses is
limited and thus there is no agreed consensus on treatment for
PP. There continues to be debate as to the best therapy both in
terms of efficacy and side effect profile. More important, given
the possibility that unrecognised or untreated attacks of periodic
paralysis may contribute to the appearance of permanent muscle
weakness in later life, there are no data on preventive treatment,
the best time to start such treatment, or the treatment of the limb-
girdle myopathy if it has already occurred.
O B J E C T I V E S
The objective of this review is to systematically review treatment
of periodic paralyses.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all the randomised controlled studies (including
crossover studies) and quasi randomised trials in which any form
of treatment for primary periodic paralysis was compared with
placebo or another therapy. Open trials and single case studies
have been included in the discussion, but not in the review.
Types of participants
We included all participants with a primary periodic paralyses di-
agnosed according to defined criteria of the ENMC International
Workshop for Periodic Paralysis (unpublished data).
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Types of interventions
We included any treatment for periodic paralysis including drugs,
alternative therapies and physical therapies.
Types of outcome measures
Primary outcomes
Our primary outcomemeasure was the reduction in attack severity
or frequency after at least eight weeks of treatment.
Secondary outcomes
The following secondary outcome measures were considered as
defined by our initial protocol:
1. Change in muscle strength determined with manual muscle
strength testing according to the 5-point Medical Research
Council (MRC) scale or by dynamometric strength testing after
at least eight weeks of treatment.
2. Change in muscle mass, determined by dual energy x-ray
absorptiometry (DEXA) after at least eight weeks of treatment.
3. Change in Quality of Life, measured with Short Form 36
(SF36) or similar after at least eight weeks of treatment.
4. Preference of treatment strategy ascertained after at least
eight weeks of treatment.
5. Adverse effects occurring by eight weeks of treatment
excluding those events considered likely to have been induced by
the withdrawal of drugs used prior to entering the study.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Neuromuscular Disease Group Tri-
als Register, MEDLINE (from January 1966 to July 2007), and
EMBASE (from January 1980 to July 2007) for randomised tri-
als and any other available international medical library sources
from the University of Milan using the terms ’periodic paralysis’,
’hypokalemic periodic paralysis’, ’hyperkalemic periodic paralysis’,
’normokalemic periodic paralysis’, Andersen’s syndrome, Ander-
sen-Tawil syndrome, periodic paralysis and cardiac arrhythmias’
as the search terms. We reviewed the bibliographies of the ran-
domised controlled trials identified.
See Appendix 1 and Appendix 2 for MEDLINE and EMBASE
strategies.
Data collection and analysis
Selection of studies
Three authors (VS, MP and TL) independently screened the ab-
stracts of potential trials retrieved from the searches. After reading
the abstracts, the papers of those studies that appeared to meet the
review inclusion criteria were obtained. These papers were then
read in detail and an inclusion/exclusion criteria form was com-
pleted. All the authors were in agreement with the selection of
studies for inclusion in this review.
Data extraction and management
Three authors independently extracted the data of the studies onto
a data extraction form.
Assessment of risk of bias in included studies
We assessed the quality of each study in terms of explicit inclusion
and exclusion criteria, explicit outcome measures, secure method
of randomisation, concealment of allocation, observer and partic-
ipant blinding, completeness of follow-up and intention to treat
analysis. Each aspect was graded with the following scale:
A: adequate
B: unclear
C: inadequate
D: not done
Data synthesis
If the data extracted had been sufficiently similar and of sufficient
quality, statistical analyses would have been performed using the
ReviewManager 4.2 software.Wewould have expressed the results
as mean difference and 95% confidence intervals for continuous
data had the mean values of the outcomes, the standard deviations
of the outcomes and the number of participants on whom the
outcome was assessed in both the treated group and placebo been
available in detail. However, although four studies were selected
that met our inclusion/exclusion criteria these did not have over-
lapping patient groups or outcome measures thus limiting data
analysis.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
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The searches found a total of 539 papers. However there were
many duplicated papers from different databases. Many were pa-
pers considering treatment in secondary periodic paralysis and
were therefore excluded. Other papers were reviews and did not
report on clinical trials. Seventeen papers remained. Of the 17
articles remaining, 11 were case reports, six were clinical trials.
Of the articles reporting clinical trials, we excluded all the studies
that were not randomised, and that did not fit the criteria for con-
sidering the study in this review leaving just three papers reporting
four studies. Of these four studies, two (Ligtenberg 1996; Links
1988) did not include our primary outcome measure having no
data on the reduction, if any, in the frequency and severity of at-
tacks. They reported change in muscle strength, which was one
of the secondary outcomes for our review, and demonstrated an
improvement in muscle strength with acetazolamide (Links 1988)
and pinacidil (Ligtenberg 1996).
The third publication (Tawil 2000), described two multicentre
randomised, double blind, placebo-controlled cross-over trials:
one involving 42 participants with HypoPP, and the other involv-
ing 31 participants with HyperPP. In each trial, two eight-week
treatment periods were separated by a washout period of at least
nine weeks; participants were their own controls. Patients were
randomised to Dichlorophenamide (DCP) or placebo in the first
eight-week period, then they were crossed to the other medication
after the wash out period, for another eight-week period.
The primary outcome variable in the HypoPP trial was the oc-
currence of an intolerable increase in attack frequency or sever-
ity, necessitating withdrawal from the treatment phase. This end
point could occur at any time during a nine-week phase, and was
distinguished from participant withdrawal or dropout because of
adverse effects or other reasons. Secondary outcomes included 1)
the average number of attacks per week over the final eight weeks
of each phase, 2) the severity-wieghted attack rate (calculated by
averaging the severity grades for each attack per week over the 8-
week period) and, 3) the participants’ preferred treatment.
The primary outcome variable in the HyperPP trial was the attack
rate (average number of attacks per week over the final eight weeks
of each phase). Secondary outcomes were; 1) severity-weighted
attack rate and, 2) the participants’ preferred treatment.
Risk of bias in included studies
The methodological quality of the included studies was adequate
in all the aspects considered, except for drop out rates (see Table
3). Periodic paralyses are rare diseases so that a placebo-controlled
crossover design as that created in the studies byTawil and cowork-
ers was necessary to create a parallel group in the study design.
The Tawil trials were randomised with a computer-generated ran-
domisation plan by using VAX-11 Fortran, one for each diagnostic
group, which included stratification by site and blocking to ensure
that each site had approximately the same number of participants
assigned to each treatment sequences. At the baseline, there were
no significant differences between the groups, in terms of number
of participants, age, mean attack rate per week and number re-
ceiving prophylactic treatment. The number of participants who
completed both treatment phases were 34/42 (81%) for the Hy-
poPP trial and 24/31 (77.4%) for the HyperPP trial. The trials by
Links 1988; and Ligtenberg 1996 were described as randomised
but the method of randomisation was not given. No drop-outs
were recorded in either of these two studies.
Effects of interventions
The results of our search found four eligible studies.
The paper by Tawil 2000 reported two trials: a trial of 42 sub-
jects HypoPP and a trial of 31 subjects with HyperPP both us-
ing dichlorphenamide (DCP). A third trial used acetazolamide in
eight subjects with HyopPP (Links 1988), while a fourth used
perindopril in four subjects with HypoPP (Ligtenberg 1996).
HypoPP
In the HypoPP trial by Tawil 2000 42 HypoPP patients were en-
rolled with 22 assigned to the placebo/DCP sequence, and 20 to
the DCP/placebo sequence. Thirty-four of 42 participants com-
pleted both treatment phases. Eight participants withdrew from
the trial: three dropped out in the first phase of run-in; two
dropped out in the first nine-week wash out period; three dropped
out in the last eight-week treatment phase. Of these last three par-
ticipants two were on DCP and they dropped out due to adverse
effects, and the other one was taking placebo and was lost to fol-
low-up.
Of the 34 participants who remained, 15 reached the end point
of an intolerable increase in attack frequency or severity. Of the
13 patients who exhibited a preference, 11 reached the end point
while taking placebo and two while taking DCP.
For the 34 participants having attack rate data while on DCP,
the mean improvement in attack rate on DCP relative to placebo
was statistically significant (P = 0.02). The mean improvement in
severity-weighted attack rate was statistically significant (P = 0.01)
on DCP relative to placebo. Fifteen of the 34 participants reached
the end point in at least one of the treatment phases. When these
were included in the analyses, the statistical significance of the
treatment became more evident (P = 0.001 for attack rate, P =
0.007 for severity-weighted attack rate).
When asked in a blinded fashion at the end of trial what treat-
ment they preferred, 15 preferredDCP, three placebo and six their
baseline medication, acetazolamide (see Table 4).
Most of the reported adverse events were those commonly as-
sociated with carbonic anhydrase inhibitors. The most common
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symptoms were confusion, difficulty with memory, difficulty con-
centrating, irritability, and depression. These adverse events ac-
counted for the two dropouts related to medication side effects
(dizziness, difficulty in concentration).
The trials by Links 1988 and Ligtenberg 1996 were short term
studies focussing on the effects of acetazolamide and pinacidil on
muscle strength and they did not assess the effects of these drugs
on attack frequency or severity. In the trial by Links 1988 eight
subjects with HypoPP were enrolled in a double blind cross over
study with acetazolamide (125 mg x 3 daily) or placebo being
given for two weeks each. Muscle strength was measured in 11
muscle groups (hip adductors, hip flexors, knee extensors, knee
flexors, shoulder abductors, elbow extensors, elbow flexors, wrist
extensors, 3 point grip, neck extensors, and neck flexors) with a
hand-held dynamometer every week and improved significantly in
seven of eight participants. The mean strength during treatment
weeks was significantly greater than during placebo weeks in all
participants (P = 0.05). Total muscle strength increased during the
second acetazolamide week (mean increase: 10%). Surface EMG
measurement performed before and after treatment showed no
change in the muscle fiber conduction velocity or power spectra.
One participant withdrew from the study because of side effects
of dizziness, nausea and tearfulness.
In one other placebo controlled double blind study (Ligtenberg
1996) of four participants with HypoPP, two showed improve-
ment of muscle strength with pinacidil. Strength was measured
using hand heldmyometer in fourmuscles (bilateral hip abductors
and knee flexors) and was measured hourly during the three hour
study period.
HyperPP
31 participants were enrolled: 15 assigned to the placebo/DCP
sequence, and 16 to the DCP/placebo sequence.
Twenty-four of 31 participants completed both treatment phases.
Seven participants withdrew from the trial: one was lost to follow-
up in the run-in phase; twodroppedout in the first nine-weekwash
out period, three participants dropped out in the first last eight-
week treatment phase. Of these last three participants, two were in
DCP, and the other one was taking placebo and was lost to follow-
up. One subject dropped out in the last eight-week treatment
phase, in DCP, for adverse effects.
Sixteen patients of 24 provided attack rate data for both treatment
phases: the mean improvement in attack rate on DCP relative to
placebo was significant (P = 0.006), and the mean improvement
in severity-weighted attack rate on DCP relative to placebo was
also significant (P = 0.02).
When asked in a blinded fashion at the end of trial what treat-
ment they preferred, 15 preferred DCP, one placebo and five their
baseline medication (see Table 5).
The adverse effects in this group were similar to those observed
in the HypoPP trial. One participant dropped out of the study
because of adverse events (dizziness, difficulty concentrating at
work) while taking DCP.
D I S C U S S I O N
The finding of only two randomised controlled trials in the litera-
ture focusing on attack frequency and severity, implies that despite
advances in molecular biology and cell physiology in the field of
skeletal channelopathies, there is still a huge gap between our sci-
entific knowledge and any evidence base for treatment strategies
in PP. Studies on treatment strategies have been limited in the
periodic paralyses probably due to the relatively ’benign’ nature
of the disorders because of the transitory nature of the paralytic
episodes. However, increasing reports on the development of a
limb-girdle myopathy show that some people with periodic paral-
ysis may be as disabled as others with muscular dystrophies. The
paucity of literature data on treatment in the periodic paralyses
may also reflect the difficulties in constructing a trial in this group
of disorders: the drop out rate may be exceedingly high to render a
trial acceptable. Consider the Tawil trial in which there was nearly
one fifth and one fourth, respectively in HyperPP and HypoPP, of
drop out rate.
The study by Tawil and co-workers demonstrates the efficacy of
DCP in reducing the frequency and severity of episodic weakness
in PP. It shows that attack rates were significantly lower during the
DCP phase than during the placebo phase in both the HypoPP
and the HyperPP trials and that 17 of the 34 participants had
to stop the placebo phase because the attack rate was intolerable.
However, the clinical details of these participants were insufficient
to identify a specific profile.
Previous studies with acetazolamide were single blind (Resnick
1968; Griggs 1970) or case reports (Raphael 1977) and were thus
not considered in our data analysis. However, all suggested a ben-
eficial effect of acetazolamide in reducing the frequency of at-
tacks. The study by Tawil and workers did not address relative ef-
ficacy of acetazolamide versus dichlorphenamide although many
patients were on acetazolamide before entering the study. A carry-
over effect was minimised in the study by Tawil and coworkers
given the short half-life of acetazolamide. We have analysed other
studies which have looked at the reduction of attack frequency
and these have included several drugs in either hypokalemic pe-
riodic paralysis or hyperkalemic periodic paralysis (see tables for
studies included and excluded in the review). ((i) nine partici-
pants with HypoPP were treated with Verapamil in a double blind
trial (Links 1998). A positive effect with verapamil was not ex-
cluded; (ii) one participant with Hyper PP with metaprotenorol
(Bendheim 1985), salbutamol (Hanna 1998; Wang 1976), DCP
(Sander 1988); (iii) Verapamil and diaxozide are described in two
clinical trials (Links 1998; Johnsen 1977b) to reduce the number
of attacks in people with HypoPP. A trial on four participants with
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HypoPP (Johnsen 1977b) indicated no benefit in treatment with
propranolol. Lithium did not seem to be beneficial in one partic-
ipant with HyperPP (Pope 1984)). These studies were small non-
radomised trials that did not in themselves offer certain alternative
treatment options to acetazolamide or DCP.
When considering Andersen-Tawil syndrome still less informa-
tion is available on treatment for the paralytic events (Djurhuus
1998; Junker 2002) so that no evidence based treatment can be
recommended for this variety of periodic paralysis.
When considering muscle weakness and the potential limb-gir-
dle myopathy that may be present in some of these people, still
less information is available to define guidelines for preventive
treatments. There are only a few studies with dichlorphenamide
(Dalakas 1983; Links 1988), using a single-blind, placebo-con-
trolled design, aimed at the prevention of persistent interattack
weakness. These studies provide encouraging results on the use of
dichlorphenamide or acetazolamide. The number of participants
in these studies is however limited and despite clinical evidence the
lack of genetic characterisation at the time represents a limitation
to the interpretation of the results. This same limitation charac-
terises another study with a potassium-channel opener, pinacidil.
Ligtenberg and coworkers (Ligtenberg 1996), demonstrated an
improvement in muscle strength in four people with hypokalemic
periodic paralysis during attacks provoked with hyperglycaemic
glucose clamp. Although encouraging these studies were too small
and anecdotal. Although the carbonic acid anhydrase inhibitors
are the current treatment options inHyperPP andHypoPP, further
studies on a larger number of participants in multicentre studies
are needed to define which drug is best for both periodic and inter-
ictal weakness comparing efficacy, side-effects and cost-benefits in
the primary periodic paralyses.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In clinical practice a single double-blind randomised placebo-
controlled cross-over trial and case reports on a limited number
of participants suggest that carbonic acid anhydrase inhibitors
reduce attack frequency and severity in the primary periodic
paralyses. However there is insufficient information to say which
of the carbonic acid anhydrase inhibitors (dichlorphenamide or
acetazolamide) is more efficacious or has fewer side effects. If
dichlorophenamide proves to be more efficacious than acetazo-
lamide, as suggested by the study by Tawil, it is worth noting
that the drug has been withdrawn by the manufacturers, except
in Italy, for reasons other than safety and effectiveness. The best
treatment for permanent muscle weakness in periodic paralysis
has not been evaluated in any randomised trial. It is yet unclear
whether attack frequency leads to permanent muscle weakness or
whether reducing the attacks prevents this progression. The best
treatment for attack frequency or permanent muscle weakness in
the periodic paralysis associated with Andersen-Tawil syndrome
has not been evaluated in any trial. In particular, in these forms of
periodic paralysis treatment options are limited by the potential
effects on the cardiac conduction system, which may be severely
involved in Andersen-Tawil Syndrome.
Implications for research
Further research is needed to determine (i) if carbonic acid an-
hydrase inhibitors are indeed beneficial and if dichlorphenamide
is better than acetazolamide when considering cost-benefit effects
and side-effects; (ii) if permanent muscle weakness may be pre-
vented or partially treated by these drugs; (iii) if specific muta-
tions respond better than others with these drugs when consid-
ering both attack frequency and severity and permanent muscle
weakness; (iv) if attacks of paralysis in Andersen-Tawil syndrome
respond to the same drugs as the other primary periodic paralysis
especially considering potential effects on the cardiac conduction
system resulting from the electrolyte imbalance; (v) if treatment
should start early in the disease course, no matter what the rate or
severity of attacks, and if this approach could reduce the risk of
developing a permanent myopathy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ligtenberg 1996
Methods Randomised, double blind, placebo-controlled.
Participants 4 participants with HypoPP, 8 matched controlled subjects.
Interventions Pinacidl vs Placebo
Outcomes Insulin sensitivity during hypergycemic glucose clamp. Improvement in muscle strength
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Links 1988
Methods Randomised, double blind, placebo-controlled cross-over trial
Participants 8 participants with HypoPP.
Interventions ACZ vs Placebo
Outcomes Improvement in muscle strength.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Tawil 2000
Methods Multicentre, randomised, double-blind, placebo-controlled, cross-over trial
Participants 42 participants with Hypokalemic Periodic Paralysis.
31 Hyperkalemic Periodic Paralysis.
Interventions DCP vs placebo
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Tawil 2000 (Continued)
Outcomes HypoPP: the primary outcome was the occurence of an intolerable increase in attack frequency or severity,
necessitatingwithdrawal from the treatment phase; a secondary outcomewas the average number of attacks
per week over the final 8 weeks of each phase. HyperPP: the primary outcome variable was the average
number of attacks per week over the final 8 weeks of each phase; other secondary outcome variables were
severity-weighted attack rate and the preferred treatment
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bendheim 1985 Case report only
Brillman 1973 Case report only
Confavreux 1991 Case report only
Dalakas 1983 Placebo-controlled case report. Not randomised and/or double blind
Djurhuus 1998 Case report only
Griggs 1983 Case report only
Hanna 1998 Case report only
Ikeda 2002 Case report only
Johnsen 1977a No randomisation
Johnsen 1977b No randomisation
Junker 2002 Case report only
Links 1994 Case report only
Links 1998 Observational study only
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(Continued)
Meola 2000 Case report only
Pope 1984 Double blind but non-randomised trial
Raphael 1977 Case report only
Riggs 1981 Case report only
Sander 1988 Case report only
Streib 1985 Case report only
Thompson 1984 Case report only
Torres 1981 Single blind non-randomised trial
Vern 1987 Case report only
Wang 1976 No randomisation
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D A T A A N D A N A L Y S E S
Comparison 1. Comparison between HypoPP and HyperPP attack rate per week on DCP relative to placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean improvement in attack
rate per week on DCP relative
to placebo
1 33 Mean Difference (IV, Fixed, 95% CI) -1.4 [-2.97, 0.17]
2 Mean improvement in
severity-weighted attack rate
per week on DCP relative to
placebo
1 33 Mean Difference (IV, Fixed, 95% CI) -3.50 [-6.38, -0.62]
Analysis 1.1. Comparison 1 Comparison between HypoPP and HyperPP attack rate per week on DCP
relative to placebo, Outcome 1 Mean improvement in attack rate per week on DCP relative to placebo.
Review: Treatment for periodic paralysis
Comparison: 1 Comparison between HypoPP and HyperPP attack rate per week on DCP relative to placebo
Outcome: 1 Mean improvement in attack rate per week on DCP relative to placebo
Study or subgroup HypoPP HyperPP
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tawil 2000 17 0.9 (1.4) 16 2.3 (2.9) 100.0 % -1.40 [ -2.97, 0.17 ]
Total (95% CI) 17 16 100.0 % -1.40 [ -2.97, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours treatment Favours control
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Analysis 1.2. Comparison 1 Comparison between HypoPP and HyperPP attack rate per week on DCP
relative to placebo, Outcome 2 Mean improvement in severity-weighted attack rate per week on DCP relative
to placebo.
Review: Treatment for periodic paralysis
Comparison: 1 Comparison between HypoPP and HyperPP attack rate per week on DCP relative to placebo
Outcome: 2 Mean improvement in severity-weighted attack rate per week on DCP relative to placebo
Study or subgroup HypoPP HyperPP
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tawil 2000 17 1.1 (1.5) 16 4.6 (5.7) 100.0 % -3.50 [ -6.38, -0.62 ]
Total (95% CI) 17 16 100.0 % -3.50 [ -6.38, -0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours treatment Favours control
A D D I T I O N A L T A B L E S
Table 1. Diagnostic criteria for primary hypokalemic periodic paralysis
Diagnostic criteria
(1) Two or more attacks of muscle weakness with documented serum K < 3.5 mEq/L
(2) One attack of muscle weakness in the proband and one attack of weakness in one relative with documented serum K < 3.5 mEq/
L in at least one attack
(3) Three of six clinical or laboratory features outlined below:
(a) Onset in the 1st or 2nd decade.
(b) Attack duration (muscle weakness involving one or more limbs) > 2 hours.
(c) Positive triggers (high CHO rich meal, rest after exercise, stress).
(d) Improvement with potassium intake.
(e) Positive family history or genetically confirmed skeletal calcium or sodium channel mutation.
(f ) Positive McManis short exercise test.
(4) Exclusion of other causes of hypokalaemia (renal, adrenal, thyroid dysfunction; renal tubular acidosis; diuretic and laxative abuse)
15Treatment for periodic paralysis (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Diagnostic criteria for primary hyperkalemic periodic paralysis
Diagnostic criteria
(1) Two or more attacks of muscle weakness with documented serum K > 4.5 mEq/L
(2) One attack of muscle weakness in the proband and one attack of weakness in one relative with documented serum K > 4.5 mEq/
L in at least one attack
(3) Three of six clinical or laboratory features outlined below:
(a) onset < 3rd decade
(b) attack duration (muscle weakness involving one or more limbs) < 2 hours
(c) positive triggers (exercise, stress)
(d) myotonia
(e) positive family history or genetically confirmed skeletal sodium channel mutation
(f ) positive McManis short exercise test
(4) Exclusion of other causes of hyperkalaemia (renal, adrenal, thyroid dysfunction; potassium-sparing diuretics use)
Table 3. Methodological quality of the included studies
Assessment criteria Evaluation
Secure method of randomisation A
Allocation concealment A
Blinding A
Completeness of follow up B
Table 4. Outcomes in HypoPP patients (Tawil 2000)
Primary outcome measure: reduction in severity or frequency at-
tacks
Reduction of number of attacks per week from 2.0757 during
placebo phase to 1.893 during DCP phase
Secondary outcome measures: change in muscle strength Not considered in this study.
Change in muscle mass (DEXA) Not considered in this study.
Change in Quality of Life Not considered in this study.
Preference of treatment strategy 15/42 pts preferred DCP; 3/42 pts preferred placebo; 6/42 pre-
ferred their baseline medication (4 were taking nothing, 1 was
taking ACZ, 1 was taking DCP at baseline). Data were not deter-
mined for 18 patients
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Table 4. Outcomes in HypoPP patients (Tawil 2000) (Continued)
Adverse events Most common AE were paraesthesia (42%) and cognitive symp-
toms (21%), responsible for 2 drop outs due to adverse events
Table 5. Outcomes in HyperPP patients (Tawil 2000)
Primary outcome measure: reduction in severity or frequency at-
tacks
Reduction of number of attacks per week from 3.798 during
placebo phase to 3.141 during DCP phase
Secondary outcome measures: change in muscle strength Not considered in this study.
Change in muscle mass (DEXA) Not considered in this study.
Change in Quality of Life Not considered in this study.
Preference of treatment strategy 15/31 pts preferred DCP; 1/31 pts preferred placebo; 5/31 pre-
ferred their baseline medication (4 were taking nothing, 1 was
taking ACZ). Data were not determined for 10 patients
Adverse effects Most common AE were paraesthesia (38%) and cognitive symp-
toms (24%), responsible for 1 drop out due to adverse events
(memory loss)
A P P E N D I C E S
Appendix 1. Ovid MEDLINE Search Strategy
1. exp Paralyses, Familial Periodic/
2. (paralys$ and periodic).mp.
3. (hypokalaemic or hypokalemic or hyperkalaemic or hyperkalemic).mp. [mp=title, original title, abstract, name of substance word,
subject heading word]
4. 2 and 3
5. 1 or 4
6. randomized controlled trial.pt.
7. controlled clinical trial.pt.
8. randomized controlled trials/
9. random allocation/
10. double-blind method/
11. single-blind method/
12. or/6-11
13. animals/ not humans/
14. 12 not 13
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15. clinical trial.pt.
16. exp clinical trials/
17. (clin$ adj25 trial$).ti,ab.
18. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).ti,ab.
19. placebos/
20. placebo$.ti,ab.
21. random$.ti,ab.
22. research design/
23. or/15-22
24. 23 not 13
25. 24 not 14
26. comparative study/
27. exp evaluation studies/
28. follow up studies/
29. prospective studies/
30. (control$ or prospectiv$ or volunteer$).ti,ab.
31. or/26-30
32. 31 not 13
33. 32 not (14 or 25)
34. 14 or 25 or 33
35. 5 and 34
36. Andersen’s Syndrome
37. Andersen- Tawil Syndrome and treatment or therapy
38. normokalemic periodic paralysis and treatment or therapy
39 Periodic paralysis and cardiac arrhythmias and treatment or therapy
Appendix 2. Ovid EMBASE Search Strategy
1. exp Periodic Paralysis/
2. (paralys$ and periodic).mp.
3. (hypokalaemic or hypokalemic or hyperkalaemic or hyperkalemic).mp. [mp=title, abstract, subject headings, heading word, drug
trade name, original title, device manufacturer, drug manufacturer name]
4. 2 and 3
5. 1 or 4
6. Randomized Controlled Trial/
7. Clinical Trial/
8. Multicenter Study/
9. Controlled Study/
10. Crossover Procedure/
11. Double Blind Procedure/
12. Single Blind Procedure/
13. exp RANDOMIZATION/
14. Major Clinical Study/
15. PLACEBO/
16. Meta Analysis/
17. phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/
18. (clin$ adj25 trial$).tw.
19. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).tw.
20. placebo$.tw.
21. random$.tw.
22. control$.tw.
23. (meta?analys$ or systematic review$).tw.
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24. (cross?over or factorial or sham? or dummy).tw.
25. ABAB design$.tw.
26. or/6-25
27. human/
28. nonhuman/
29. 27 or 28
30. 26 not 29
31. 26 and 27
32. 30 or 31
33. 5 and 32
WH A T ’ S N E W
Last assessed as up-to-date: 13 November 2007.
Date Event Description
27 April 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 3, 2004
Review first published: Issue 1, 2008
Date Event Description
14 November 2007 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Valeria Sansone andMarta Panzeri wrote the review. Thera Links reviewed the papers together with Valeria Sansone andMarta Panzieri.
Michael Rose helped with data analysis. Giovanni Meola and all other authors revised and discussed the paper.
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D E C L A R A T I O N S O F I N T E R E S T
Doctors Sansone, Panzeri, Links and Meola are involved in the NIH-funded grant on acetazolamide versus dichlorphenamide in
periodic paralyses.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acetazolamide [therapeutic use]; Carbonic Anhydrase Inhibitors [therapeutic use]; Dichlorphenamide [therapeutic use]; Hypokalemic
Periodic Paralysis [∗drug therapy]; Paralysis,Hyperkalemic Periodic [∗drug therapy]; Pinacidil [therapeutic use]; RandomizedControlled
Trials as Topic
MeSH check words
Humans
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